According to a market analysis by Persistence Market Research, the global CAR T-cell treatment market had a value of US$ 1.2 billion in 2020 and is projected to grow to US$ 2.8 billion by 2031, representing a CAGR of 5.6% over the forecast period (2021-2031). CAR T-cell therapy, a subset of T-cell therapy or a method of treating cancer cells, commands around 27% of the market for T-cell therapy as a whole.
The development of CAR T-cells for therapeutic applications is anticipated to be fueled by the rising incidence of cancer. Artificial T-cell receptors may be used in the therapy of a number of malignancies, as has been generally accepted.
Request for Free Sample Copy@ https://www.persistencemarketresearch.com/samples/28264
The process of creating CAR T-cells starts with the patient’s T-cells being removed, followed by apheresis, and then the patient’s T-cells are sent to the production facility. CAR T-cell production is now limited to a few number of factories, most of which are found in the United States and Europe. According to Persistence Market Research, the global CAR T-cell therapy market will grow at a CAGR of 5.6% from 2017 to 2031. This growth is primarily attributable to the growing number of CAR T-cell clinical trials, the involvement of key players in manufacturing, and the rising demand for cancer therapy.
Get up to 20% discount on Full Report Purchase @ https://www.persistencemarketresearch.com/checkout/28264
Car T-Cell Therapy Market Industry Research by Category
Product
-
- Yescarta (axicabtagene ciloleucel)
- Kymriah (tisagenlecleucel)
- JCAR017 (lisocabtagene maraleucel)
- bb2121
Indication
-
- Relapsed Large B-cell Lymphoma
- Acute Lymphoblastic Leukemia (ALL)
- Multiple Myeloma
End User
-
- Car T-Cell Therapy at Hospitals
- Car T-Cell Therapy at Cancer Treatment Centers
Request For Customization @ https://www.persistencemarketresearch.com/request-customization/28264
Competitive Landscape
Companies providing CAR T-cell therapy are vigorously seeking to strengthen their position through collaborations, approvals, acquisitions, and agreements with established as well as emerging market players.
-
- In May 2019, a Japanese government panel approved Novartis to sell Kymriah in Japan for $306,000 for treating the young population with acute lymphoblastic leukaemia (ALL) and the adult population with diffuse large B-cell lymphoma (DLBCL).
- In August 2017, Gilead Science acquired Kite Pharma Inc., an industry leader in the emerging field of cell therapy.
- In December 2017, Gilead Science acquired Cell Design Labs Inc. This acquisition benefits Gilead in the attainment of new technology platforms that will enhance research & development efforts in cellular therapy.
Companies
-
- Novartis AG
- Gilead Sciences Inc.
- Celgene Corporation
- bluebird bio, Inc.
Category-wise Insights
Why is Demand for Yescarta (axicabtagene ciloleucel) Rising Rapidly?
-
- In terms of product, Yescarta (axicabtagene ciloleucel) holds a high share of over 57% in 2021. Yescarta (axicabtagene ciloleucel) is a treatment for large B-cell lymphoma, which is used when conventional treatment methods do not work effectively.
- Large B-Cell Lymphoma Holds highest Market Share by Indication?
- In terms of indication, relapsed large B-cell lymphoma holds approximately 90% market share in 2021. This is a condition when the lymphoma does not respond to treatment or when the response to treatment lasts for a short period.
About Us
Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.
Contact Us
Persistence market research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com